EcoDrugPlus

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSCVAG00000022075
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSCVAG00000013780
Gene Symbol: ALOX5
3 Cross references
212 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSCVAG00000013746
Gene Symbol: ALOX5AP
3 Cross references
201 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Like

Ensembl ID : ENSCVAG00000004663
Gene Symbol: LOC107103814
3 Cross references
200 Possible Orthologues:

Arg8-Vasotocin Receptor-Like

Ensembl ID : ENSCVAG00000016840
Gene Symbol: LOC107096985
3 Cross references
203 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSCVAG00000005941
Gene Symbol: AVPR1A
3 Cross references
186 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSCVAG00000022742
Gene Symbol: AVPR2
3 Cross references
210 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSCVAG00000010460
Gene Symbol: AVPR2
3 Cross references
166 Possible Orthologues:

Aromatase

Ensembl ID : ENSCVAG00000011244
Gene Symbol: LOC107085369
3 Cross references
252 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSCVAG00000000551
Gene Symbol: LOC107095267
2 Cross references
191 Possible Orthologues:

Aurora Kinase A

Ensembl ID : ENSCVAG00000008888
Gene Symbol: AURKA
3 Cross references
230 Possible Orthologues:

Aurora Kinase B-Like

Ensembl ID : ENSCVAG00000001696
Gene Symbol: LOC107092931
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).